Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) on Thursday announced the availability of its US Food and Drug Administration (FDA) approved Cinacalcet Tablets in the United States.
Dr. Reddy's Cinacalcet Tablets are a therapeutic equivalent generic version of Sensipar (cinacalcet) Tablets. The Sensipar brand and generic market had US sales of approximately USD312m MAT for the 12 months ending in July 2020, according to IQVIA Health.
Cinacalcet Tablets are available in 30 mg, 60 mg and 90 mg tablets in a bottle count size of 30.
Cinacalcet is a medication used to treat secondary hyperparathyroidism, parathyroid carcinoma and primary hyperparathyroidism.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US